(firstQuint)An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment.

 In Part One, 8 subjects with moderate hepatic impairment (Child Pugh Scale B) and 8 matched healthy subjects will be enrolled.

 In Part 2, 8 subjects with mild hepatic impairment (Child-Pugh Scale A) and 8 matched healthy subjects will be enrolled.

 In Part 3, 3 subjects with severe hepatic impairment (Child-Pugh Scale C) will be enrolled.

 Parts 2 and 3 will only be initiated if the criteria per protocol is met in Part One.

 The pharmacokinetics and safety profiles will be compared between hepatic impaired subjects and healthy subjects.

.

 An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment@highlight

To evaluate and compare the pharmacokinetics and safety of ONO-2745/CNS 7056 in subjects with the hepatic impairment and matched healthy subjects.

